Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

141. Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage

Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage BestBets: Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage Elevation of serum magnesium may improve clinical outcome after aneursymal subarachnoid haemorrhage Report By: Daniel Horner - ST4 Emergency Medicine / Critical Care Search checked by Craig Ferguson - SpR Emergency Medicine Institution: Manchester Royal Infirmary Date Submitted: 1st May (...) 2010 Date Completed: 27th January 2011 Last Modified: 27th January 2011 Status: Green (complete) Three Part Question In a patient presenting with [aneurysmal subarachnoid haemorrhage] does [early elevation of serum magnesium by administration of intravenous magnesium sulphate] lead to a reduction in [subsequent vasospasm incidence, morbidity or mortality rates] Clinical Scenario A 40 year old female attends the emergency department as a standby call. Her partner gives you a history of acute

2011 BestBETS

142. The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial Full Text available with Trip Pro

The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial To determine whether nightly administration of melatonin, magnesium, and zinc improves primary insomnia in long-term care facility residents.Double-blind, placebo-controlled clinical trial.One long-term care facility in Pavia, Italy.Forty-three participants with primary insomnia (22 in the supplemented group, 21 in the placebo group (...) ) aged 78.3 ± 3.9.Participants took a food supplement (5 mg melatonin, 225 mg magnesium, and 11.25 mg zinc, mixed with 100 g of pear pulp) or placebo (100 g pear pulp) every day for 8 weeks, 1 hour before bedtime.The primary goal was to evaluate sleep quality using the Pittsburgh Sleep Quality Index. The Epworth Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire (LSEQ), the Short Insomnia Questionnaire (SDQ), and a validated quality-of-life instrument (Medical Outcomes Study 36-item Short

2011 EvidenceUpdates Controlled trial quality: predicted high

143. Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 Full Text available with Trip Pro

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 Cumulative sensory neurotoxicity (sNT) is the dose-limiting toxicity of oxaliplatin, which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant settings. In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT.Patients with colon cancer undergoing (...) adjuvant therapy with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were randomly assigned to Ca/Mg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo, in a double-blinded manner. The primary end point was the percentage of patients with grade 2 or greater sNT at any time during or after oxaliplatin-based therapy by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; version 3) criteria. An oxaliplatin-specific sNT

2011 EvidenceUpdates Controlled trial quality: uncertain

144. Magnesium Sulphate for Fetal Neuroprotection Full Text available with Trip Pro

Magnesium Sulphate for Fetal Neuroprotection Magnesium Sulphate for Fetal Neuroprotection - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 33, Issue 5, Pages 516–529 Magnesium Sulphate for Fetal Neuroprotection PRINCIPAL AUTHORS, x Laura Magee , MD Vancouver BC x Diane Sawchuck , RN, PhD Vancouver BC x Anne Synnes , MD Vancouver BC x Peter von Dadelszen , MBChB Vancouver BC x THE MAGNESIUM SULPHATE FOR FETAL (...) as a subscribed user or . Click to view the full text on ScienceDirect. Abstract Objective To provide guidelines for the use of antenatal magnesium sulphate (MgSO 4 ) for fetal neuroprotection of the preterm infant. Options Antenatal MgSO4 administration should be considered for fetal neuroprotection when women present at ≤ 31+6 weeks with imminent preterm birth, defined as a high likelihood of birth because of active labour with cervical dilatation ≥ 4 cm, with or without preterm pre-labour rupture

2011 Society of Obstetricians and Gynaecologists of Canada

145. Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis

Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis Cahill AG, Odibo AO, Stout MJ, Grobman WA, Macones GA, Caughey AB Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of magnesium treatment, for pregnant women at high risk of delivery before 32 weeks gestation, for the prevention of cerebral palsy in pre-term infants. Based on the evidence available, magnesium

2011 NHS Economic Evaluation Database.

146. Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth

Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Scientific Impact Paper No. 29 August 2011Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth 1. Background The prevalence of preterm birth is increasing. 1 While the survival of infants born preterm has improved, 2 the prevalence of cerebral palsy has risen. 3 The incidence of cerebral palsy decreases significantly with increasing (...) to reduce the effects of this disabling condition on individuals, families, health care and society. 2. Neuroprotection In the late 1990s studies of infants born to mothers given magnesium sulphate to prevent eclamptic seizures or as tocolysis showed a reduction in rates of cystic periventricular leucomalacia (PVL) and cerebral palsy. In those babies born preterm and exposed to magnesium sulphate 8 the odds ratio for cerebralpalsywas0.14(95%CI0.05–0.51). 9 Althoughtheexactmechanismofactionofmagnesium

2011 Royal College of Obstetricians and Gynaecologists

147. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study

Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

148. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. (Abstract)

Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Magnesium sulphate remains the drug of choice for both prevention and treatment of women with eclampsia. Regimens for administration of this drug have evolved over the years, but have not yet been formally evaluated.To assess the comparative effects of alternative regimens for the administration of magnesium sulphate when used for the care of women with pre-eclampsia or eclampsia, or both.We searched (...) the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2010).Randomised trials comparing different regimens for administration of magnesium sulphate used for the care of women with pre-eclampsia or eclampsia, or both.All four review authors assessed trial quality and extracted data independently.We identified 17 studies of which six (866 women) met the inclusion criteria: two trials (451 women) compared regimens for women with eclampsia and four (415 women) for women with pre

2010 Cochrane

149. Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study

Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

150. Efficacy and Tolerability of Split-Dose Magnesium Citrate: Low-Volume (2 Liters) Polyethylene Glycol vs. Single- or Split-Dose Polyethylene Glycol Bowel Preparation for Morning Colonoscopy (Abstract)

Efficacy and Tolerability of Split-Dose Magnesium Citrate: Low-Volume (2 Liters) Polyethylene Glycol vs. Single- or Split-Dose Polyethylene Glycol Bowel Preparation for Morning Colonoscopy Preparation regimens for morning colonoscopy are suboptimal. The aim of this study was to test the efficacy and tolerance of a split-dose magnesium citrate-low-volume (2 liters) polyethylene glycol (PEG) regimen for morning colonoscopy.A total of 232 patients were randomly assigned to receive 4 liters PEG (...) (day before procedure; group 1, n=79), 2 liters PEG (day before procedure) followed by another 2 liters PEG (day of procedure; group 2, n=80), or magnesium citrate (250 ml, day before procedure) followed by 2 liters PEG (day of procedure; group 3, n=73). The quality of bowel cleansing, tolerability, and adverse effects in group 3 were compared with those in groups 1 and 2.Satisfactory bowel preparation was more frequently reported for group 3 than for group 1 (75% vs. 51%, P=0.001) and was similar

2010 EvidenceUpdates Controlled trial quality: uncertain

151. Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets

Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Company: Pozen Application No.: 022511 Approval Date: 4/30/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

152. SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution

SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution Drug Approval Package: SUPREP (sodium sulfate, potassium sulfate, magnesium sulfate) NDA #022372 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, magnesium sulfate) Oral Solution Company: Braintree Laboratories, Inc. Application No.: 022372 Approval Date: 08/05/2010 Persons with disabilities having problems

2010 FDA - Drug Approval Package

153. Magnesium Sulfate for Asthma Attack

Magnesium Sulfate for Asthma Attack Magnesium Sulfate for Asthma Attack – TheNNTTheNNT Intravenous Magnesium Sulfate Given During an Asthma Attack 3 for prevented hospital admission In Summary, for those who took the magnesium: Benefits in NNT 67% saw no benefit 33.3% of severe asthmatics were helped by preventing hospital admission 1 in 3 were helped (preventing hospital admission if patient is a "severe asthmatic") None were helped (preventing hospital admission if patient is not a "severe (...) asthmatic") Harms in NNT 0% of severe asthmatics were harmed by serious side effects 100% of non-severe asthmatics were neither helped nor harmed None were harmed (serious side effects, vital sign abnormalities) View As: NNT % Source: Efficacy Endpoints: Hospital admission Harm Endpoints: Tachycardia, tremor Narrative: This review included 7 trials, (N = 665) of which 5 were adult and 2 pediatric. Magnesium sulfate was administered early in the study period, in the first 60 minutes in 5 of the studies

2010 theNNT

154. Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials

Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

155. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review (Abstract)

Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review To systematically review rates of neurologic outcomes reported in childhood for the preterm fetus exposed to antenatal magnesium sulfate.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register, CENTRAL (The Cochrane Library 2008, Issue 3), relevant references from retrieved articles, and abstracts submitted to major congresses.We sought all randomized controlled trials (RCTs (...) ) of antenatal magnesium sulfate with neurologic outcomes reported for the fetus.Five eligible RCTs with 6,145 fetuses were identified; in four studies (4,446 fetuses) the primary intent was neuroprotection of the fetus. Methods of the Cochrane Collaboration were used to analyze the data. Antenatal magnesium sulfate therapy given to women at risk of preterm birth substantially reduced the risk of cerebral palsy in their children (relative risk [RR] 0.69; 95% confidence interval [CI] 0.54-0.87; five trials

2009 EvidenceUpdates

156. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks` gestation: a systematic review and metaanalysis Full Text available with Trip Pro

Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks` gestation: a systematic review and metaanalysis We conducted a systematic review and metaanalysis of randomized controlled trials to determine whether magnesium sulfate administered to women at risk of preterm delivery before 34 weeks of gestation may reduce the risk of cerebral palsy in their children. Six trials involving 4796 women and 5357 infants were included. Antenatal magnesium (...) sulfate was associated with a significant reduction in the risk of cerebral palsy (relative risk [RR], 0.69; 95% confidence interval [CI], 0.55-0.88), moderate or severe cerebral palsy (RR, 0.64; 95% CI, 0.44-0.92), and substantial gross motor dysfunction (RR, 0.60; 95% CI, 0.43-0.83). There was no overall difference in the risk of total pediatric mortality (RR, 1.01; 95% CI, 0.89-1.14). Minor side effects were more frequent among women receiving magnesium sulfate. In conclusion, magnesium sulfate

2009 EvidenceUpdates

157. Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial Full Text available with Trip Pro

Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial The goal was to study whether postnatal magnesium sulfate infusion could improve neurologic outcomes at discharge for term neonates with severe perinatal asphyxia.Forty term (> or =37 weeks of gestation) neonates with severe perinatal asphyxia were studied in a prospective, longitudinal, placebo-controlled trial. Patients were assigned randomly to receive either 3 doses of magnesium sulfate infusion at 250 mg (...) of 20) of patients had severe encephalopathy. The mean serum magnesium concentration in the treatment group remained at > or =1.2 mmol/L for 72 hours after the first infusion. At discharge, 22% (4 of 18) of infants in the treatment group had neurologic abnormalities, compared with 56% (10 of 18) of infants in the placebo group. Also, neuroimaging (head computed tomography) performed on day 14 yielded abnormal findings for fewer infants in the treatment group than in the placebo group (16% vs 44

2009 EvidenceUpdates Controlled trial quality: predicted high

158. The Efficacy of Administration of Intravenous Magnesium Sulfate for Improved Ventricular Rate Control or Rhythm Control in Patients with Non-postoperative Atrial Fibrillation and Atrial Flutter

The Efficacy of Administration of Intravenous Magnesium Sulfate for Improved Ventricular Rate Control or Rhythm Control in Patients with Non-postoperative Atrial Fibrillation and Atrial Flutter "The Efficacy of Administration of Intravenous Magnesium Sulfate for Im" by Mary Schindeler < > > > > > Title Author Date of Graduation 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers MS, PA-C Second Advisor Rob Rosenow (...) PharmD, OD Rights . Abstract INTRODUCTION: Standard treatment for atrial tachyarrthmias, such as atrial fibrillation or atrial flutter, involves rate and rhythm control. Previous studies have looked at the electrophysiologic effects of magnesium on impulse formation and propagation, and theorized it could be beneficial in treatment for atrial tachycardias. There recently have been studies about magnesium sulfate and its utility in establishing rate and rhythm control in patients with atrial

2009 Pacific University EBM Capstone Project

159. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis

Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

160. A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate

A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.